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Ebola virus disease (EVD) is an acute, serious and fatal 
illness caused by the Ebola virus. EVD was first identified 
in 1976 during two simultaneous outbreaks, one in Nzara, 
Sudan, and the other in Yambuku, Democratic Republic of 
Congo [1]. The latter occurred in a village near the Ebola 
River, from which the disease takes its name. Since its 
emergence, several EVD outbreaks have occurred in Africa. 
The 2013–2015 Ebola outbreak in West Africa is the largest 
and the most complex one to date. There have been more 
cases and deaths resulting from this outbreak than those 
reported for all previous outbreaks. The disease has also 
spread between countries, beginning in Guinea and then 
spreading across land borders to Sierra Leone and     
Liberia [2]. Of the countries afflicted, Guinea, Liberia and 
Sierra Leone have been the most severely affected; these 
countries also have very weak health systems, lack human 
and infrastructural resources, and have only recently 
emerged from long periods of conflict and instability, mak-
ing control of the outbreak more challenging. 
After emergence of the outbreak, numerious countries 
and organizations have provided assistance to aid in Ebola 
control. Ebola is transmitted through direct contact with 
patients or contaminated materials. Effective outbreak con-
trol relies on the application of a package of interventions, 
including case management, surveillance and contact trac-
ing, good laboratory service, safe burials, and social mobi-
lization.  
Because Ebola is highly infectious and fatal, early diag-
nosis is key for patient isolation, treatment and transmission 
prevention. Confirmative diagnosis of EVD depends on 
laboratory diagnosis [3]. Because of the weak health system 
and infrastructure, West African countries have limited la-
boratory diagnosis capabilities, and all laboratory diagnosis 
are dependent on mobile laboratories from other countries. 
To summarize the laboratory practices and provide implica-
tions for future field diagnosis of emerging infectious dis-
eases, we collected and analyzed information about mobile 
laboratories from the websites of the Health Department of 
Sierra Leone, World Health Organization (WHO), or other 
related organizations, or during laboratory exchanges. 
EVD laboratory diagnosis includes non-specific diagno-
sis and specific diagnosis. Non-specific laboratory indica-
tors of EVD include a low platelet count, an initially de-
creased white blood cell count followed by an increased 
white blood cell count; and abnormalities in blood clotting 
often consistent with disseminated intravascular coagulation 
(DIC) [4]. Confirmative diagnosis of EVD is based specific 
laboratory diagnosis. Confirmation of EVD includes isolat-
ing the virus, detecting its RNA or proteins, or detecting 
antibodies against the virus. Isolating the virus by cell cul-
ture, detecting the viral RNA by polymerase chain reaction 
(PCR) and detecting proteins by enzyme-linked immuno-
sorbent assay (ELISA) are methods used to directly detect 
the pathogen. Detecting antibodies against the virus is an 
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indirect method to show the infection. Although each of the 
available tests could provide confirmative information about 
the infection, these tests can only be used during an appro-
priate period of the infection (Table S1). Within days after 
experiencing symptoms, viral antigen and nucleic acid from 
the virus can be detected from in the blood or serum sam-
ples of patients. IgM antibodies are detectable two days 
after symptom onset and IgG antibodies can be detected 
6–18 d after symptom onset. For corpse where blood sample 
is unavailable, oral swabs may be obtained and nucleic acid 
or viral isolation can be performed.  
Since the outbreak of EVD, many countries and organi-
zations have provided assistances in an attempt to control 
the outbreak in Sierra Leone. After March 2014, a total of 
14 laboratories from 7 countries or organizations have been 
setup in Sierra Leone (Table S2). Of these laboratories, the 
Kenema Government Hospital Lassa Diagnosis Lab was the 
first laboratory to initiate Ebola diagnosis. However, this 
laboratory was shut down on August 7 2014 because of an 
infection in facility. Canada’s lab started diagnosis early on 
July 2 2014. Their laboratory was located in Kailahun 
where Ebola was first transmitted from Guinea into Sierra 
Leone. England began its first laboratory in Kerry Town on 
October 28, and then in Port Loko and Makeni on Decem-
ber 6 and 10, respectively. China’s mobile laboratory began 
EVD diagnosis on September 28. The European Union be-
gan three laboratories in December 2014, which moved 
from Liberia or Guinea where the incidence decreased near 
the end of the outbreak. Although there are several testes 
available for laboratory diagnosis of EVD, the most com-
monly used is real time PCR assay. All laboratories em-
ployed reverse transcription PCR (RT-PCR) assay to detect 
Ebola virus RNA. The WHO also defined PCR and real 
time PCR methods and protocols, including primers, probes 
and reaction conditions, to specifically detect the 2014 
Ebola virus.  
Of the mobile laboratories, those from the USA, China, 
South Africa and England, are mainly used for diagnosis. 
Samples were collected by sampling teams and sent to 
nearby laboratories. For sample reception and subsequent 
detection, laboratories have adopted different procedures 
(Table S3). For China Jui and England Port Loko, samples 
were received and stored to be tested in one or more batches 
of per day. For USA Bo and South Africa Lakka labs, sam-
ples were subjected to treatment and detection once re-
ceived. These four labs have used different detection 
equipment and procedures. For Ebola diagnosis, samples 
were inactivated before subsequent analysis. Both heat and 
chemical inactivation were used by the four labs. Except for 
the China Jui lab, all labs employed only chemical inactiva-
tion. Nucleic acid extraction methods differed between labs. 
The Lakka lab used a manual extraction method, while the 
Bo lab used only automatic extraction; the other two labs 
used both manual and automatic methods. All the four labs 
used quantitative PCR (QPCR) to detect viral nucleic acids. 
In terms of the target choice, the Jui and Bo labs used a 
two-target detection strategy, and when either of the targets 
showed positive results, the sample was defined as Ebola 
infection-positive. The running time for each batch of sam-
ple ranged from 4–6 h. The human resources ranged from 
4–12 persons, and the detection capacity per batch varied 
from 28–200 samples. 
The China mobile laboratory was deployed in Freetown 
and began EVD diagnosis on September 28 2014. Because 
this was the first time a Chinese professional staff worked 
with this biosafety level 4 (BSL4) pathogen, great attention 
was placed on biosafety. The detection capacity during ear-
ly stages was set to 24 samples per day. With proved skills 
and familiarity with the practice, the detection capacity 
steadily increased. To improve diagnosis quality and effi-
cacy, a series of measures have been implemented (Table 
1). For EVD diagnosis, an RT-PCR assay was developed to 
specifically detect the Zaire Ebola virus, and three RT-PCR 
kits were licensed for an urgent evaluation. These kits pro-
vided highly qualified diagnostic reagents for the laborato-
ry. In addition to the diagnostic kit, many other measures 
have been undertaken to improve quality and efficacy. 
These measures included sample reception, pre-treatment, 
nucleic acid extraction, amplification and case definition 
criteria. To improve information check efficacy, samples 
and their information were photographed and then checked 
by staff outside of the BSL3 cabinet. An automatic nucleic 
acid extraction machine was introduced to improve extrac-
tion efficacy. With these optimizations, the detection capac-  
Table 1  Improvement of detection quality and efficacy by China mobile laboratory 
Factors restricting efficacy and quality Efficacy improvement measures Improved quality or efficacy 
Quality 
Protocol and adherence Strict training and exercise All persons strictly adhere to protocols, ensuring quality 
Amplification Two target, replicate, in-house control Reducing possibility of false positive or negative 
Result interpretation Combining raw data, curve and duplicates Generate confirmative results 
Efficacy 
Sample number instable Coordinate sample sending Sample number was increased and relative stable 
Complicated sample information check Photographed and sent outside of P3 for checking Checking time was reduced over 75% 
Capacity of heat Inactivation Heat inactivation with high capacity incubator Batch capacity improved 3 times 
Manual extraction Replacement with automatic robot Batch capacity improved 4 times and time reduced 60% 
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ity was increased to at least 200 samples per day. Because 
of these improvements, the China mobile laboratory suc-
cessfully passed the external quality control assessment 
initiated by the WHO with 100% accuracy, making it one of 
the most high-performance labs participating the assess-
ment. 
Because the Ebola virus is a BSL4 pathogen, biosafety is 
extremely important to the staff handling the samples. Dur-
ing the outbreak, we visited the US Bo, England Port Loko 
and South Africa Lakka laboratories. These laboratories 
used different biosafety countermeasures. As shown in Ta-
ble S4, there were differences in personal protection equip-
ment, laboratory protection level, sample inactivation, and 
high-throughput diagnosis. Ebola virus is a pathogen that 
should be manipulated under BSL4 condition, however, 
under field conditions, it is difficult to completely meet 
these criterion. Labs from South Africa and England used 
negative pressure biosafety gloves, while the China lab used 
BSL3 mobile laboratory. Surprisingly, that the US Centers 
for Disease Control and Prevention (CDC) labs did not use 
any biosafety equipment, the only protections included 
gloves and visors. All labs used automatic extraction robots. 
The US CDC used two types of extraction machines, 
15-sample and 96-sample automatic extraction machines. 
The 15-sample machine was used for small batches of sam-
ples, while 96-sample machine for large batches. The China 
Lab adopted level A protection, which is complicated and 
expensive. Because of the relatively complicated proce-
dures, the China lab diagnosed only 1–2 batches of samples 
per day.  
Our analysis and summary of mobile laboratory practices 
are important for our future works. The 2013–2015 EVD 
outbreak in West Africa is the most severe public health 
disaster in recent years. China, has begun to have increas-
ingly important roles in international affairs. Since the out-
break occurred, China participated in the international 
campaign against the disaster, which was a valuable oppor-
tunity for China’s public health professions. The Ebola con-
trol and prevention mission represented many firsts for 
China’s public health professions: the first public health 
action oversea, first handling a level 4 pathogen, and first 
time extending control front against an infectious disease to 
oversea. Before this outbreak, we had no experience with 
the control of infectious diseases overseas. We must face 
many new challenges, ensuring our mobile laboratory is 
safe, cooperating and/or competing with labs from other 
countries, cooperating with the local health department. 
We have successfully setup our mobile laboratory in 
Freetown, Sierra Leone. Through systematic optimization 
and improvement in diagnosis procedures and protocols, we 
significantly improved the diagnosis quality and efficacy.  
Our detection capacity has steadily increased and is compa- 
rable to or higher than that of labs from other countries. We 
diagnosed approximately 20% of the total samples in the 
whole country. We successfully passed the external quality 
control test with 100% accuracy in the shortest amount of 
time. During this test, two of the six participating labs did 
not pass the assessment with 100% accuracy. This indicated 
the high quality and efficacy of our mobile laboratory.  
Although we successfully participated in the campaign 
against EVD outbreaks, we also faced challenges. Ebola 
was first discovered in 1976, although approximately forty 
years have passed, there has been no significant scientific 
improvement in understanding of this disease in our coun-
try, while America has invested in not only basic research, 
but also in the prevention and control of outbreaks. 
EVD diagnosis in West Africa is mainly dependent on 
RT-PCR assays, which include sample inactivation, nucleic 
acid extraction and amplification. The complete process 
requires 4–6 h, which is a relatively long period of time for 
the highly infectious, fatal and rapid progress EVD. 
Point-of-care diagnosis assays are urgently needed. Howev-
er, there are no commercial reagents for these diagnosis 
assays for EVD.  
Taken together, mobile laboratories have played im-
portant roles in the identification and control of EVD out-
break. Through the use of our mobile laboratory, we have 
accumulated much experience with field laboratory diagno-
sis. Good practice from other laboratories will be valuable 
for our in future work. 
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